Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Resurrecting the 'yuppie vaccine'

A Correction to this article was published on 08 October 2014

This article has been updated

The only vaccine ever approved to protect against Lyme disease was pulled off the market in 2002, and drugmakers have yet to offer an alternative. What's taking so long? Cassandra Willyard investigates.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Change history

  • 22 September 2014

     In the July 2014 issue, the piece “Resurrecting the 'yuppie vaccine'” (Nat. Med. 20, 698, 2014) stated that “LYMErix originated in the late 1980s in a laboratory at the Yale School of Medicine at Yale University” and that “[b]y 1992, SmithKline Beecham had licensed the vaccine.” However, it failed to mention the work of a team of German researchers, including Markus Simon and Ulrich Schaible at the Max Planck Institute and Michael Kramer and Reinhard Wallich of the University of Heidelberg, who published initial key findings laying the groundwork for the LYMErix vaccine against Lyme disease. The error has been corrected in the HTML and PDF versions of this article.


  1. Fikrig E., Barthold, S.W. & Flavell, R.A. Science 250, 553–556 (1990).

    Article  CAS  Google Scholar 

  2. Steere, A.C. et al. N. Engl. J. Med. 339, 209–215 (1998).

    Article  CAS  Google Scholar 

  3. Gross, D.M. et al. Science 281, 703–706 (1998).

    Article  CAS  Google Scholar 

  4. Poland, G.A. Clin. Infect. Dis. 52 (suppl. 3), s253–s258 (2011).

    Article  Google Scholar 

  5. Silverman, E. The Star-Ledger (26 February 2002).

    Google Scholar 

  6. Sigal, L.H. et al. N. Engl. J. Med. 339, 216–222 (1998).

    Article  CAS  Google Scholar 

  7. Luft, B.J., Dunn, J.J. & Lawson, C.L. J. Infect. Dis. 185 (suppl. 1), S46–S51 (2002).

    Article  CAS  Google Scholar 

  8. Wressnigg, N. et al. The Lancet 13, 680–689 (2013).

    Article  CAS  Google Scholar 

  9. Small C.M., Ajithdoss, D.K., Rodrigues Hoffmann, A., Mwangi, W. & Esteve-Gassent M.D. PLoS One 9, e88245 (2014).

    Article  Google Scholar 

  10. Steere, A.C., Drouin, E.E. & Glickstein, L.J. Clin. Infect. Dis. 52 (suppl. 3), s259–s265 (2011).

    Article  CAS  Google Scholar 

  11. Stricker, R.B. & Johnson, L. Lancet Infect. Dis. 14, 12 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Willyard, C. Resurrecting the 'yuppie vaccine'. Nat Med 20, 698–701 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing